

Influenza B Virus, B/Great Lakes/1739/1954

Catalog No. NR-3179

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID),
National Institutes of Health

Manufacturer:

Parke, Davis and Company, PH-43-62-841

Product Description:

Reagent: Seed Virus

Virus Classification: *Orthomyxoviridae, Influenzavirus B*

Species: Influenza B virus

Strain/Isolate: B/Great Lakes/1739/1954; also B/Great Lakes/54

NIAID Class: Research Reference Reagent

Source: National Centers for Disease Control

Donor Passage History (# of passages):

Chicken embryo (4)/ Mouse (10)/ Chicken embryo (32)

Producer Passage History (# of passages):

Chicken embryo (2)

Comments: Sequence information is available for influenza B virus, B/Great Lakes/1739/1954 at the [Influenza Research Database](#)

Note: BEI Resources was asked to distribute this virus preparation from NIAID's historical repository. Historical characterization information is shown below in the Functional Activity and Purity sections (tests performed in June, 1969). Recent characterization information is shown on the Certificate of Analysis.

Material Provided/Storage:

Composition: Allantoic fluid

Volume: 1.0 mL

Storage Temperature: -60°C or colder

Functional Activity (June 1969):

Infectivity:

Conditions: 10 to 11 day chicken embryo

TCID₅₀: 1.6 x 10⁴ per mL

Complement Fixation:

Conditions: 2 units of activated complement (C'); 30 minutes at 37°C

Titer: 1:4

Hemagglutination:

Conditions: Human type O red blood cells; 1 hour at room temperature

Titer: 1:640

Purity (June 1969):

Serum Neutralization Breakthrough: Negative

Bacterial Sterility: Negative

Mycoplasma: Negative

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Influenza B Virus, B/Great Lakes/1739/1954, NR-3179."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see <http://www.cdc.gov/biosafety/publications/bmb15/BMBL.pdf>.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. The Tissue Culture Infectious Dose 50% (TCID₅₀) endpoint is the 50% infectious endpoint in tissue culture. The TCID₅₀ is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the cultures inoculated, just as a Lethal Dose 50% (LD₅₀) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the TCID₅₀ provides a measure of the titer (or infectivity) of a virus preparation.
2. Mogabgab, W. J., et al. "Isolation and Cytopathogenic Effect of Influenza B Viruses in Monkey Kidney Cultures." *Proc. Soc. Exp. Biol. Med.* 89 (1955): 654–659. PubMed: 13254857.

ATCC® is a trademark of the American Type Culture Collection.

